Artículo de revista
Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 treated with tocilizumab
Fecha
2020Registro en:
Pediatr. Rep. 2020, 12, 142–148
10.3390/pediatric12030029
Autor
Niño Taravilla, Carmen
Espinosa Vielma, Yazmín P.
Otaola Arca, Hugo
Poli Harlowe, Cecilia
Tapia, Lorena I.
Ortiz Fritz, Paula
Institución
Resumen
We describe a case of Pediatric Inflammatory Multisystem Syndrome temporally associated
with SARS-CoV-2 (PIMS-TS) in an 8-year-old child. The patient developed multiorgan dysfunction,
including mixed shock, cardiac dysfunction with myocarditis, pneumonia, acute kidney failure,
and gastrointestinal involvement characterized by inflammation of the wall of the bowel
and pancreatitis. After treatment with Tocilizumab and corticoid therapy, he presented clinical
improvement and normalization of inflammatory markers. PIMS-TS is a new disease developed in a
small percentage of patients, so a high degree of suspicion is necessary to establish the diagnosis.
Supportive care is of paramount importance. The use of Tocilizumab to control the inflammatory
response is likely to be beneficial, but the best immunotherapeutic agent has not yet been established.
Randomized clinical studies should be run to determine the best treatment.